Miturut laporan saka Grand View Research "Kabutuhan medis sing ora cocog lan inisiatif pamrentah kanggo nyuda gangguan psikiatri lan neurologis nyopir pasar kanggo terapi sistem saraf pusat (CNS).
Miturut WHO, ekonomi global ilang amarga depresi lan kuatir luwih saka USD $ 1 triliun saben taun lan basis pasien kesehatan mental sing mundhak sacara global bakal nambah ekonomi sing ilang $ 16 triliun ing 2030. Pasar duwe kesempatan wutah sing kuat ing mangsa ngarep. lan pemain utama nggunakake strategi pemasaran sing beda kayata pangembangan produk anyar, kolaborasi, ekspansi geografis, penggabungan lan akuisisi, lan persetujuan produk anyar, kanggo nguatake posisi. Laporan kasebut nggambarake manawa pasar terapi sistem saraf pusat global samesthine bakal tekan $ 205.0 milyar ing taun 2028 lan samesthine bakal tuwuh ing CAGR udakara 7.4% nganti 2028.
Laporan kasebut terus: "Ana produk pipa sing kuat dening perusahaan farmasi utama ... lan liya-liyane bakal nyepetake wutah pasar sajrone ramalan. Kajaba iku, perusahaan farmasi liyane uga aktif melu pangembangan terapi novel lan nandur modal akeh kanggo ngembangake terapi efektif kanggo perawatan penyakit sing ana gandhengane karo CNS. Bioteknologi aktif ing pasar saiki kalebu: Pasithea Therapeutics Corp., Alkermes plc, Passage Bio, Inc., Acadia Healthcare Company, Inc., atai Life Sciences.
Umume obat pangembangan fase pungkasan yaiku kanggo perawatan gangguan neurodegeneratif kayata penyakit Alzheimer, multiple sclerosis, penyakit Parkinson, lan sclerosis lateral amyotrophic ... macem-macem indikasi kelainan neurodegeneratif. Kajaba saka penyakit neurodegeneratif, migren, skizofrenia, lan epilepsi minangka indikasi penyakit CNS utama sing duwe calon obat potensial ing pipa. Perusahaan farmasi nggunakake strategi kayata pangembangan produk, penggabungan lan akuisisi, lan kolaborasi kanggo nguatake posisi ing pasar.
APA sing kudu dijupuk saka ARTIKEL INI:
- Most of the late phase development drugs are for the treatment of neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis… some of the potential drugs that could be commercialized in the next five to eight years for the treatment of various indication of neurodegenerative disorders.
- According to WHO, the global economy loses due to depression and anxiety is more than USD $1 trillion per year and rising patient base of mental health globally is expected to increase the economy loses by USD $16 trillion in 2030.
- Besides, other pharmaceutical companies are also actively involved in the development of novel therapies and investing heavily to develop effective therapeutics for the treatment of CNS associated diseases.
